Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors
- PMID: 34992247
- DOI: 10.1038/s41587-021-01126-9
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors
Abstract
Small molecules that stabilize inactive protein conformations are an underutilized strategy for drugging dynamic or otherwise intractable proteins. To facilitate the discovery and characterization of such inhibitors, we created a screening platform to identify conformation-locking antibodies for molecular probes (CLAMPs) that distinguish and induce rare protein conformational states. Applying the approach to KRAS, we discovered CLAMPs that recognize the open conformation of KRASG12C stabilized by covalent inhibitors. One CLAMP enables the visualization of KRASG12C covalent modification in vivo and can be used to investigate response heterogeneity to KRASG12C inhibitors in patient tumors. A second CLAMP enhances the affinity of weak ligands binding to the KRASG12C switch II region (SWII) by stabilizing a specific conformation of KRASG12C, thereby enabling the discovery of such ligands that could serve as leads for the development of drugs in a high-throughput screen. We show that combining the complementary properties of antibodies and small molecules facilitates the study and drugging of dynamic proteins.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Similar articles
-
Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors.J Comput Aided Mol Des. 2022 Aug;36(8):591-604. doi: 10.1007/s10822-022-00467-0. Epub 2022 Aug 5. J Comput Aided Mol Des. 2022. PMID: 35930206 Free PMC article.
-
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.Mol Pharm. 2021 Sep 6;18(9):3509-3518. doi: 10.1021/acs.molpharmaceut.1c00426. Epub 2021 Aug 19. Mol Pharm. 2021. PMID: 34410132
-
Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.Bioorg Chem. 2021 May;110:104825. doi: 10.1016/j.bioorg.2021.104825. Epub 2021 Mar 13. Bioorg Chem. 2021. PMID: 33774492
-
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.J Exp Clin Cancer Res. 2022 Jan 19;41(1):27. doi: 10.1186/s13046-021-02225-w. J Exp Clin Cancer Res. 2022. PMID: 35045886 Free PMC article. Review.
-
Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.J Intern Med. 2020 Aug;288(2):183-191. doi: 10.1111/joim.13057. Epub 2020 Apr 7. J Intern Med. 2020. PMID: 32176377 Review.
Cited by
-
In Silico Evaluation of the Thr58-Associated Conserved Water with KRAS Switch-II Pocket Binders.J Chem Inf Model. 2023 Mar 13;63(5):1490-1505. doi: 10.1021/acs.jcim.2c01479. Epub 2023 Feb 28. J Chem Inf Model. 2023. PMID: 36854010 Free PMC article.
-
Disulfi de constrained Fabs overcome target size limitation for high-resolution single-particle cryo-EM.bioRxiv [Preprint]. 2024 May 13:2024.05.10.593593. doi: 10.1101/2024.05.10.593593. bioRxiv. 2024. PMID: 38798381 Free PMC article. Preprint.
-
Allosteric nanobodies to study the interactions between SOS1 and RAS.Nat Commun. 2024 Jul 23;15(1):6214. doi: 10.1038/s41467-024-50349-2. Nat Commun. 2024. PMID: 39043660 Free PMC article.
-
Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations.Sci Rep. 2025 Jul 10;15(1):24843. doi: 10.1038/s41598-025-07532-2. Sci Rep. 2025. PMID: 40640254 Free PMC article.
-
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor.J Med Chem. 2022 Nov 10;65(21):14614-14629. doi: 10.1021/acs.jmedchem.2c01120. Epub 2022 Oct 27. J Med Chem. 2022. PMID: 36300829 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous